Literature DB >> 12684666

Mutational analysis of the nf2 tumour suppressor gene in three subtypes of primary human malignant mesotheliomas.

Holger Schipper1, Thilo Papp, Georg Johnen, Heidi Pemsel, Ralf Bastrop, Klaus-Michael Müller, Thorsten Wiethege, Malgorzata Jaworska, Michael Krismann, Dietmar Schiffmann, Qamar Rahman.   

Abstract

Fourteen primary human malignant mesothelioma (HMM) samples obtained from 14 patients were screened for point mutations and microdeletions/microinsertions in exons 1-16 of the chromosome 22q-located tumour suppressor gene neurofibromin 2 (nf2) by single strand conformation polymorphism (SSCP) analysis. In one tumour (7%) a 10 basepair microdeletion of exon 10 was detected by SSCP and subsequently characterised in detail by sequencing. Deletion of the second nf2 allele in laser-microdissected regions of the 10 bp mutation-harbouring tumour was demonstrated by denaturing gradient gel electrophoresis (DGGE) analysis. Simultaneous comparative genomic hybridisation (CGH) analysis also showed losses at chromosome 22q. Our data indicate that functional loss of the NF2 protein may be involved in the formation of a subset of HMMs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12684666

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  3 in total

1.  Chromosomal alterations in early stages of malignant mesotheliomas.

Authors:  Frank Simon; Georg Johnen; Michael Krismann; Klaus-Michael Müller
Journal:  Virchows Arch       Date:  2005-10-19       Impact factor: 4.064

Review 2.  Chemotherapy and targeted therapies for unresectable malignant mesothelioma.

Authors:  Ronan Joseph Kelly; Elad Sharon; Raffit Hassan
Journal:  Lung Cancer       Date:  2011-05-28       Impact factor: 5.705

Review 3.  The genetic susceptibility in the development of malignant pleural mesothelioma.

Authors:  Ombretta Melaiu; Federica Gemignani; Stefano Landi
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.